Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
about
State of the Art: Newer biomarkers in heart failureSoluble ST2 Testing: A Promising Biomarker in the Management of Heart FailureGalectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitisEmerging risk biomarkers in cardiovascular diseases and disordersCurrent Understanding of the Pathophysiology of Myocardial Fibrosis and Its Quantitative Assessment in Heart Failure.Novel biomarkers for cardiovascular risk prediction.Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3.Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure.The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failureUtility of galectin-3 as a prognostic biomarker in heart failure: where do we stand?Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I.Galectin-3: a novel biomarker for the prognosis of heart failure.Mas receptor mediates cardioprotection of angiotensin-(1-7) against Angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress.Correlation between growth differentiation factor-15 and collagen metabolism indicators in patients with myocardial infarction and heart failure.Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart FailureGalectin-3 Is Elevated and Associated With Adverse Outcomes in Patients With Single-Ventricle Fontan Circulation.Galectin-3 and Risk of Heart Failure and Death in Blacks and Whites.Soluble ST2 for Prediction of Heart Failure and Cardiovascular Death in an Elderly, Community-Dwelling PopulationIL-34 is associated with the presence and severity of renal dysfunction and coronary artery disease in patients with heart failureThe impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease.Heart failure and galectin 3.Beyond cardiac troponin: recent advances in the development of alternative biomarkers for cardiovascular disease.The potential role of IL-33/ST2 signaling in fibrotic diseases.Current applications of biomarkers in cardiomyopathies.Candidate biomarkers in heart failure with reduced and preserved ejection fraction.Using biomarkers to guide heart failure management.Clinical relevance of sST2 in cardiac diseases.Interleukin 1 Receptor-Like 1 Protein (ST2) is a Potential Biomarker for Cardiomyopathy in Duchenne Muscular Dystrophy.Using the galectin-3 test to predict mortality in heart failure patients: a systematic review and meta-analysis.Clinical Phenotyping of Heart Failure with Biomarkers: Current and Future Perspectives.ST2 and Galectin-3: Ready for Prime Time?Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.Do we need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2).Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure.Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2.Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis.Prognostic Value of Serial Galectin-3 Measurements in Patients With Acute Heart Failure.
P2860
Q27027899-3387466E-D132-4234-AA02-E168915C1657Q28066438-AB585127-4C4F-4344-A3B6-DF966A1E882AQ28069174-5CA6E0B9-3423-4CCA-8613-49615B182418Q28081614-038D69B2-BA27-421E-BD84-B405A21B16BCQ33595504-160AA6D8-0A4C-49B8-ABEA-7819732C2403Q33615459-22D862FE-9736-4C19-87FD-CC1889D9EB7EQ33897327-95B407BD-FF56-4619-A19B-63058ABCC9D8Q33912126-DC6F732F-3111-4CA6-9823-9C4EE61D90E0Q34408467-E221A42F-75BB-4304-A8F9-942C215A86FAQ34472413-BD75FD83-B5D4-47A6-B5EA-E3634B4AB0C9Q35286926-CCA92A26-9289-49A2-9E7D-93198D036941Q35662925-E76C0BE6-9179-4EDE-8951-473FD506021EQ36385583-3D4521C3-2BD1-403B-A419-8916CBAB6FC4Q36476862-75376EC9-CC91-4FDA-B63C-ACF6E5525F32Q36578465-B867BD5A-75C2-47C4-BA59-EFDBF9AE1539Q36757833-253FFB01-8414-4EF0-8E08-2573497B695EQ36877769-A987A5D4-0358-489B-BEEC-2CA710D930ADQ36956715-78CBEBC2-E6C2-4253-8980-EE242D98E5D5Q37240346-B73DD071-0FB1-44B6-8D58-2A1F65B07EBBQ37508213-B556790D-061E-493F-BCF3-E4DBE8928564Q37602424-E39FD75D-8617-40C4-AF39-220A0D6CB75EQ37681556-5FA04D83-AC9F-439F-8092-DB7E781C5223Q38269044-E604AD3B-8798-4295-9544-0C7CDCE301BCQ38353580-DDD9B9C3-13D1-4D6D-B20C-9408C0B88660Q38424483-CD6F60F6-ED27-45D5-B90B-F84758427F00Q38536678-637394E4-3D68-4415-BBCC-2F70D89D7F18Q38572500-B17F8BB3-8DF5-4FDE-9D99-7A02435E92B6Q38613842-34DADB0A-4331-43EA-9F5F-D4A02D6DC624Q38626970-76880CDC-41E6-463D-9103-C8EC25D97011Q38640186-3AB37AA1-9E21-41B9-AAA3-CF0F943C21DAQ38727409-BD00D6F6-7CF6-4BB7-9C17-3C72C07EBDB2Q38756838-A3D8AEED-D72D-4810-B72D-00D727D58B1CQ38816590-8FFDA602-DDB6-4191-961A-0F37C29AD417Q38977493-C9D236AB-18D4-4CEC-AF82-D6E84492BEC0Q39059489-E7F17D5E-4A92-43D8-A687-BC9C46282C9CQ41731823-6E556B01-4BEC-47EE-BFEA-4217287E1817Q47138839-5E93434E-F96C-4278-BDF9-30841CC15763Q47329197-19B4E512-0EA0-4AF4-B57E-03FCA37DFA65Q47843525-D2607EC3-7879-4697-A09C-D71AB287044CQ47944097-813142B3-F52B-4136-9725-2245DB759610
P2860
Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@en
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@nl
type
label
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@en
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@nl
prefLabel
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@en
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@nl
P2093
P50
P1476
Head-to-head comparison of 2 m ...... cation: ST2 versus galectin-3.
@en
P2093
Agustin Urrutia
Amparo Galán
Judith Peñafiel
Marta de Antonio
P304
P356
10.1016/J.JACC.2013.07.087
P407
P577
2013-09-24T00:00:00Z